<DOC>
	<DOC>NCT01758185</DOC>
	<brief_summary>The objective of this study was to evaluate the safety and immunogenicity of one inactivated split influenza vaccine, a primarily Chinese-marketed trivalent vaccine.</brief_summary>
	<brief_title>Safety and Immunogenicity Study of Aleph Inactivated Split Influenza Vaccine</brief_title>
	<detailed_description>A total of 3308 subjects were stratified equally into four age groups and receive either influenza vaccine or recombinant hepatitis b vaccine (seen as placebo). Systematic and local adverse reactions were reported for 28 d after the vaccination. Antibody levels were detected through hemagglutination inhibition assay before vaccination (Baseline) and 28d after the vaccination.</detailed_description>
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>more than three years in good healthy current infectious fever or acute disease upper respiratory infectious symptom within 6m a history of allergy laboratory confirmed influenza autoimmune disease have get influenza vaccine since 2008</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Inactivated split influenza vaccine</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Safety</keyword>
	<keyword>Consistence</keyword>
</DOC>